drugset / Trial / NCT05998941
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study used a single-arm, open phase II multicenter trial design. All eligible subjects received TQB2868 plus platinum-based chemotherapy with or without bevacizumab. A total of 39 subjects will be enrolled.
Timeline
- Start
- 2023-08
- Primary completion
- 2025-02
- Completion
- 2025-06
Outcome
Outcome not reported
Stopped: “Slow progress in development, the sponsor decided to withdraw and no longer proceed.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | TQB2868 | Protein / enzyme biologic | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Paclitaxel | Small molecule | — | — |